China Ramps Up Diplomacy As World Comes Calling For Vaccines

Summary

  • India, one of the world’s largest drugmakers, has put curbs on exports of AstraZeneca to meet its domestic demand.
  • Amid a shortage of covid drugs, countries grappling with the increasing number of deaths and infections have turned to China for vaccines.
  • China already has supplied covid vaccines to over 80 countries.

China’s vaccine diplomacy has been gaining fruits as more and more countries are relying on it for covid drugs. China already has supplied covid vaccines to over 80 countries.

Following India’s curbs on vaccine exports and America’s focus on meeting its domestic demand for Covid-19 drugs, China is emerging as the largest provider of vaccines to the world.

Why has India stopped vaccine supplies to other countries?

To meet its domestic demand, India, one of the world’s largest drug manufacturers, has put curbs on exports of AstraZeneca, the vaccine being produced by the Serum Institute of India. India has recently witnessed a shortage of vaccines amid a surge in covid cases, forcing it to block exports. India had delivered over 49 million vaccines to 120 countries before the curbs.

Meanwhile, the US and the European Union have decided to inoculate their citizens first instead of rushing to the aid of the needy countries, a decision which some leaders have criticized.

Also Read: Did Sustainable Growth Get A Boost As An Aftermath Of COVID-19?

Pic Credit: Pixabay.


Also Read:
COVID-19: How Well Have The Vaccine Makers Performed?

Why are Chinese vaccines in demand?

Amid a shortage of covid drugs, countries grappling with the increasing number of deaths and infections have turned to China for vaccines. Brazil, the Philippines, Pakistan, and countries in Africa and Europe, such as Zimbabwe, Serbia, and Hungary, have placed orders for Chinese drugs.

The World Health Organisation (WHO) was looking to India for supplies for its Covax initiative, which seeks to distribute covid vaccines equitably to needy countries. The global health organization is now looking to China for supplies. It plans to approve vaccines from Sinopharm and Sinovac.

According to the state-owned Sinopharm, it has delivered over 50 million vaccines to various countries so far and would ramp up its production capacity to one billion doses this year.

Pic Credit: Pixabay.


Also Read:
Canada backs AstraZeneca’s COVID-19 vaccine but includes coagulation warning

What is China’s vaccine diplomacy?

Although China has been providing free vaccines to many countries since it rolled out the shots, WHO’s clearance of its drugs would pave the way for their supplies to many more nations.

China hopes to build a close partnership with other countries, including its neighbours in South Asia, which are facing a new Covid wave, through its vaccine diplomacy. It is offering free covid aid, relaxation in drug procurement and support in vaccine production.

Meanwhile, US President Joe Biden’s administration has also decided to waive off intellectual property rights on Covid vaccines following demand from many countries, including India, where a second wave of the pandemic has overwhelmed the hospitals and medical facilities with patients.

Also Read: ResApp (ASX:RAP) to initiate study probing the cough-COVID-19 relationship


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK